<DOC>
	<DOCNO>NCT01893632</DOCNO>
	<brief_summary>Benzodiazepine dependence grow public health problem evidenced-based treatment approach available . Approximately 683,000 individual meet past year criterion sedative-hypnotic use disorder US 2010 , prevalence great heroin methamphetamine dependence . The commonly prescribed sedative-hypnotic agent benzodiazepine . Chronic use induces pharmacodynamic tolerance GABA neurotransmitter system individual physiological dependence find benzodiazepine difficult discontinue withdrawal rebound symptom , include autonomic arousal , depression , anxiety , insomnia . Available evidence-based treatment approach primarily direct therapeutic user benzodiazepine meet criterion substance use disorder , general consensus gradual taper benzodiazepine period several month optimal approach . However , patient benzodiazepine dependence typically refer inpatient detoxification treatment , rapidly taper patient benzodiazepine . Protracted withdrawal symptom frequently persist discharge , predispose patient relapse . More effective pharmacotherapeutic strategy need treatment benzodiazepine dependence outpatient setting .</brief_summary>
	<brief_title>Gabapentin Treatment Benzodiazepine Dependence</brief_title>
	<detailed_description>Gabapentin proven safe well-tolerated medication low abuse liability , thereby make ideal use outpatient setting . The proposed Exploratory Development research project double-blind randomize controlled clinical trial compare efficacy gabapentin placebo outpatient treatment benzodiazepine dependence . The goal project study effect gabapentin participant ' benzodiazepine use facilitate taper-to-abstinence model , participant actively use benzodiazepine study entry , gabapentin treatment introduce , participant counsel gradually discontinue benzodiazepine use study period gabapentin treatment maintain . A modified version Medical Management use facilitate compliance study medication study procedure , include clinical instruction gradually reduce benzodiazepine use 25 % per week . Benzodiazepines prescribe propose study ; participant continue obtain benzodiazepine prescribe nonprescribed source .</detailed_description>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Meets DSMIVTR criterion BZD dependence 2 . Using BZDs minimum 5 day per week past 28 day 3 . Between age 18 60 4 . Able provide inform consent 1 . Any current DSMIVTR Axis I psychiatric disorder , BZD dependence , might require intervention course study , include schizophrenia , bipolar disorder , major depressive disorder panic disorder . 2 . Receiving psychotropic medication BZDs 3 . Evidence physiological BZD withdrawal ( pulse &gt; 100 ; blood pressure &gt; 140/90 ) 4 . History BZD withdrawal seizure withdrawal delirium 5 . History allergic reaction GBP 6 . Pregnancy , lactation , failure female patient use adequate contraceptive method 7 . Unstable physical disorder might make participation hazardous medical history 8 . Subjects current DSMIVTR diagnosis substance dependence , exception nicotine caffeine history ; dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Benzodiazepines</keyword>
	<keyword>clonazepam</keyword>
	<keyword>alprazolam</keyword>
	<keyword>Klonopin</keyword>
	<keyword>Xanax</keyword>
	<keyword>diazepam</keyword>
	<keyword>Valium</keyword>
	<keyword>lorazepam</keyword>
	<keyword>Ativan</keyword>
</DOC>